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&7148) and $9200, respectively, and the cost per addi›
tional quality adjusted life year (QALY) was $44 000
and $27 200. The authors concluded that these costs
were similar to those of a number of existing medical
interventions. However, their lay responder model
used costs from a police responder pilot. It is likely that
the cost per QALY of a public access scheme will be
much higher, owing to the large number of
defibrillators needed to provide adequate coverage.
Unlike automated external defibrillators used by a
police service, public access defibrillators are fixed to a
location, and the location of future arrests cannot be
predicted precisely from the location of previous
arrests.
Conclusions
Targeted placement of defibrillators in public places
such as airports and shopping centres, frequented by a
large number of susceptible people, could, at best,
increase overall survival from 5.0% to 6.3%. Further
expansion of the coverage of public access defibrilla›
tors to enable lay use in all potentially suitable sites
would require much greater resources and would pro›
duce little additional improvement in survival. Public
access defibrillators should not be provided in
preference to the expansion of defibrillation given by
first responders or increased cardiopulmonary resusci›
tation by bystanders.
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Angiotensin converting enzyme insertion or deletion
polymorphism and coronary restenosis:
meta›analysis of 16 studies
François Bonnici, Bernard Keavney, Rory Collins, John Danesh
Abstract
Objective To assess the association between genotype
at the insertion or deletion polymorphism of the
angiotensin converting enzyme gene and risk of
coronary restenosis after percutaneous coronary
intervention.
Design Meta›analysis of studies before July 2001 that
reported on these genotypes and risk of coronary
restenosis after a percutaneous coronary intervention,
with or without coronary stenting.
Results 16 studies, involving 4631 patients
undergoing a percutaneous coronary intervention,
yielded 1683 patients with restenosis after a mean
weighted follow up of 5.5 months. The combined
odds ratio for restenosis in people with the DD
genotype was 1.23 (99% confidence interval 1.03 to
1.46). When studies were grouped by size, however,
the combined odds ratios for restenosis in people with
the DD genotype were 1.94 (1.39 to 2.71) for studies
with less than 100 cases, 1.33 (0.92 to 1.93) for studies
with 100›200 cases, and 0.92 (0.72 to 1.18) for studies
with more than 200 cases (trend P=0.02). Similarly,
when studies were grouped by genotyping
procedures, significantly larger odds ratios were found
in the studies that did not conceal disease status from
laboratory staff and in the studies that did not use a
second polymerase chain reaction amplification to
reduce genetic mistyping.
Conclusion Compared with other studies, larger and
more rigorous studies show a weaker association
between the angiotensin converting enzyme gene DD
genotype and restenosis. Publication bias or detection
biases can produce artefactual associations at least as
large as those that might be expected for common
polymorphisms in complex diseases, suggesting the
need for larger and more rigorous genetic
epidemiological investigations than are now
customary.
Introduction
Restenosis after a percutaneous coronary intervention is
one of the principal limitations of this technique, occur›
ring in up to 50% of patients undergoing the procedure
without stenting and in about 20% of patients receiving
stents.1 Despite a lack of good evidence that susceptibil›
ity to restenosis is genetically determined, several studies
have investigated polymorphisms that might be associ›
ated with restenosis. As the angiotensin converting
enzyme insertion or deletion (I/D) polymorphism is
strongly associated with plasma and cellular angiotensin
converting enzyme concentrations, it has been consid›
ered a strong candidate.2 It has been suggested that the
incidence of coronary restenosis after a percutaneous
coronary intervention is much higher in patients with
the angiotensin converting enzyme DD genotype (which
is associated with particularly high plasma angiotensin
converting enzyme levels) than in others, but published
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observational studies are conflicting.3–18 To help clarify
the evidence we considered all available relevant studies
in a meta›analysis.
Methods
We sought studies published before July 2001 of the
angiotensin converting enzyme insertion or deletion
polymorphism and coronary restenosis after a percuta›
neous coronary intervention, with or without coronary
stenting, by computer based searches (Medline, Embase,
PubMed, Web of Science), reviews of reference lists, hand
searching relevant journals, and correspondence with
authors. For the electronic searches we used combina›
tions of key words relating to the angiotensin converting
enzyme gene (for example, angiotensin converting
enzyme, ACE, polymorphism, insertion/deletion, I/D,
D/I) and to restenosis (for example, coronary, restenosis,
percutaneous, angioplasty, PTCA, stent, stenting). We
included all identified studies. Articles in languages
other than English were translated.
From each study we abstracted (supplemented by
correspondence with investigators) geographical loca›
tion, race of participants, numbers of cases and
controls, the coronary intervention procedure, defini›
tion of restenosis, frequency of insertion or deletion
genotypes, genotyping methods and laboratory proce›
dures, mean age, and duration of follow up.
We estimated odds ratios by comparing cases who
developed coronary restenosis after a percutaneous
coronary intervention with controls who did not within
the same study. We did this under the prior hypothesis
that individuals who were homozygous for the
angiotensin converting enzyme D allele were predis›
posed to restenosis compared with those with the ID or
II genotypes.19
Results
We identified 16 relevant studies concerning a percuta›
neous coronary intervention, 11 without stenting
(2535 patients) and five with stenting (2096 patients),
yielding 4631 patients (94% white) undergoing such
interventions.3–18 All the studies used quantitative com›
puter assisted methods to define restenosis as a
narrowing of the coronary diameter by 50% or more at
follow up compared with the minimal luminal
diameter immediately after intervention. Overall, 1683
of these patients (mean age 60 years) developed
coronary restenosis after a mean weighted follow up of
5.5 months. The studies were conducted in Australia,
Chile, France, Germany, Italy, Japan, Spain, Turkey, the
United Kingdom, and the United States.3–18 Following
correspondence with the authors, it was confirmed that
genotyping had been performed by staff unaware of
the disease status of the patients in four of the five
studies with more than 100 cases,6 16–18 compared with
only two of the 11 studies with less than 100 cases.4 8
Overall, the combined odds ratio for restenosis in
people with the DD genotype was 1.23 (99% confidence
interval 1.03 to 1.46; test for heterogeneity ÷_=24.1,
df=15, P=0.06: fig 1). We found no significant heterogen›
eity between studies of percutaneous coronary interven›
tion with stenting and those without stenting (combined
odds ratios for the DD genotype of 1.17 v 1.27
respectively; ÷_=0.23, df=1, P=0.6). When studies were
grouped by size, however, the combined odds ratios for
restenosis were 1.94 (1.39 to 2.71) for the 11 studies with
less than 100 cases,3–5 7–9 11–15 1.33 (0.92 to 1.93) for the
three studies with 100›200 cases,6 10 16 and 0.92 (0.72 to
1.18) for the two studies with more than 200 cases
(fig 2).17 18 A test for trend across these three groups of
studies was significant (÷_=5.6, df=1, P=0.02). Similar
results were observed when odds ratios for restenosis
were calculated per D allele in these three groups (1.74 v
1.00 v 0.98, respectively). When studies were grouped by
genotyping procedures, significantly larger odds ratios
were observed in the studies that did not conceal disease
status from laboratory staff (combined odds ratios for
the DD genotype of 1.87 v 1.02 respectively, ÷_=9.7, df=1,
P=0.002)3 5 7 9–15 and in the studies that did not use a
second polymerase chain reaction amplification to
reduce mistyping of angiotensin converting enzyme ID
heterozygotes as DD (1.55 v 1.13, respectively; ÷_=4.05,
df=1, P=0.03).3 5–7 10 12–14
Discussion
Weaker associations between the angiotensin convert›
ing enzyme DD genotype and restenosis were found in
larger and more rigorous studies than in other studies.
We had observed a similar trend in published studies of
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Fig 1 Meta›analysis of 16 published studies of angiotensin
converting enzyme insertion or deletion polymorphism and coronary
restenosis
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Fig 2 Meta›analysis of published studies of angiotensin converting
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the angiotensin converting enzyme DD genotype and
myocardial infarction.19 These findings have important
implications for genetic epidemiology, suggesting that
publication bias or detection biases can produce
artefactual associations at least as large as those that
might be realistically expected for common polymor›
phisms in complex diseases.
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Science commentary: Coronary angioplasty and stenting
Two main interventions are available for opening up
blocked coronary arteries: balloon angioplasty and
open heart surgery. In percutaneous coronary angio›
plasty a wide lumen catheter is fed from the groin up to
the aortic root and into the coronary arteries. A guide
wire is passed through the catheter and across the
stenosis in the coronary artery. The wire is used to guide
a balloon (with a stent mounted on it if necessary) into
the diseased section of the artery. The balloon is inflated,
pushing the atheroma outwards and enlarging the
lumen of the artery. A stent can be expanded to fit the
artery. Once the stent is in place (confirmed by
angiography), the wires and the catheter are removed.
Arterial restenosis remains a serious problem after
percutaneous coronary angioplasty. It tends to occur
within three months of the procedure and is due to
proliferation of smooth muscle as a reaction to vessel
injury. Restenosis used to occur in over 30% of patients
after percutaneous coronary angioplasty, but with the
use of stents and advances in stent design and
improved techniques for implanting them the rates
now lie between 10% and 20%.1 2 This is comparable to
the 10% of vein grafts that are lost in the year after
bypass grafting. The main risk factors for restenosis
after percutaneous coronary angioplasty are diabetes,
thrombus formation or inflammation in the coronary
tree, and small vessel size.
Two recent trials found no difference between
percutaneous coronary angioplasty plus stenting and
bypass surgery for death or myocardial infarct in
What is already known on this topic
Restenosis after a percutaneous coronary
intervention is one of the principal limitations of
the technique
Genotype at the angiotensin converting enzyme
insertion or deletion polymorphism is proposed
to be important in restenosis
What this study adds
Weaker associations between the angiotensin
converting enzyme DD genotype and restenosis
were found in larger and more rigorous studies
than in other studies
Publication bias or detection biases, or both, can
produce artefactual associations at least as large as
those that might be expected for common
polymorphisms in complex diseases
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